Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Fireworks likely at Senate drug pricing hearing today

Senators fire broadsides: "I hope CEOs don't blame everyone but themselves"

- PMLiVE

Novartis and Syncona back new Swiss biotech Anaveon

Founders focused on IL-2 Receptor Agonists

- PMLiVE

FDA and Flatiron extend real world evidence collaboration

Roche-owned specialists at forefront of big data analysis

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Q&A: Nicola Walsby

Gemma Jones interviews Syneos Health's Managing Director PR UK

Doctors Letter

Health Literacy in Practice: Doctor’s Letter

If a patient was given their results directly, how could we make it into something they could understand and, most importantly, act on?

Cuttsy + Cuttsy

- PMLiVE

Combining therapies and combining research

The strategy for retaining antibiotic security

- PMLiVE

Three agencies join forces to form ONEHealth

Veronique Cotrel will head up the new agency

- PMLiVE

Ipsen buys rare disease group Clementia in $1.3bn deal

Will acquire lead multiple rare disease candidate palovarotene

- PMLiVE

Novartis in-licenses Akcea’s novel cardiovascular therapy

Lp(a) targeting therapy could treat millions

Are you capitalising on your pharma exhibition presence?

When it comes to exhibition success, pharma companies have lots of things to consider. This includes making sure that you have quality pharma exhibition stands that sparks conversations. But, to...

Apex Events and Exhibitions

- PMLiVE

Roche buys gene therapy specialist Spark for $4.3bn

Can compete with rival Novartis in fast-developing area

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links